In a first-in-human, Phase I clinical trial (NCT05168423), researchers evaluated the safety and early efficacy of intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR epitope 806 and interleukin-13 receptor α2 (IL13Rα2) in 18 patients with recurrent, EGFR-amplified glioblastoma. The gene discussed is EGFR; the disease is glioblastoma.